
|Articles|January 16, 2015
- Vol 32 No 1
- Volume 32
- Issue 1
Talk Radio, 2 am
Author(s)Richard M. Berlin, MD
I’m driving home from the ER, not ready for sleep, eaten up by memories of my mistakes...
Advertisement
I’m driving home from the ER,
not ready for sleep, eaten up
by memories of my mistakes,
a man on the radio telling me
not to worry because I can learn
to control my mind. He says
thoughts are like puppies
we can paper-train and teach
to be obedient. He says
one day that puppy will calm down,
cuddle up, and lick my face.
But who is this guy kidding?
My mind isn’t a puppy tonight-
it’s a wild tiger,
and it’s ripping out my heart.
Articles in this issue
almost 12 years ago
Does TMS Hold Promise for Generalized Anxiety Disorder?almost 12 years ago
Managing Anxiety in the Medically Illalmost 12 years ago
Mental Health Benefits of Exercise in Childrenalmost 12 years ago
Gone Girl by Gillian Flynnalmost 12 years ago
How to Fix the Broken Mental Health System: Ten Crucial Changesalmost 12 years ago
Brain Stimulation With ECT: Neuroscience Insights From an Old Treatmentalmost 12 years ago
In With the Old, Out With the Newalmost 12 years ago
The Dynamics of Psychosis: Therapeutic Implicationsalmost 12 years ago
A Rational Suicide?Advertisement
Related to this article

In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.

2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.

Explore how clinicians subtype depression using severity, stressors, suicidality, sleep, and anxiety patterns to sharpen diagnosis, guide treatment, and build trust.

Learn more about the randomized, double-blind phase 2b study of naturally derived psilocybin in MDD, and more.

In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Ketamine for Treatment-Resistant Depression: Practical Clinical Considerations
2
sNDA Submitted: Caplyta for the Treatment of Bipolar Mania
3
Real-World Lecanemab Outcomes in Alzheimer Disease, Reported at 3 Years
4
Mixed Results From Phase 3 Data for AR1001 in Alzheimer Disease
5



